MedTrace Logo

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

NCT03890952 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-24

No results posted yet for this study

Summary

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent glioblastoma

Conditions

  • Recurrent Adult Brain Tumor

Interventions

DRUG

Nivolumab

Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

DRUG

Bevacizumab

Treatment with the combination of Nivolumab and bevacizumab every 2 weeks

Sponsors & Collaborators

  • Herlev Hospital

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Ulrik Lassen

    lead OTHER

Principal Investigators

  • Ulrik Lassen, MD, PHD · Rigshospitalet, Denmark

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2023-02-01
Completion
2024-08-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03890952 on ClinicalTrials.gov